Keyphrases
Systematic Meta-analysis
100%
Confidence Interval
95%
Meta-analysis of Randomized Controlled Trials
76%
Meta-analysis
53%
Risk Ratio
52%
COVID-19
48%
Myocardial Infarction Patients
38%
Post-acute
38%
Colchicine
38%
Lopinavir
38%
Hydroxychloroquine
38%
Azithromycin
28%
Randomized Controlled Trial
27%
Random Effects Model
24%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
19%
Asymptomatic COVID-19 Infection
19%
Transcatheter Aortic Valve Replacement
19%
Updated Meta-analysis
19%
Integrase Inhibitors
19%
Restrictive Cardiomyopathy
19%
Constrictive Pericarditis
19%
Lobular Capillary Hemangioma
19%
Atrial Fibrillation
19%
Enamel Matrix Derivative
19%
Periodontal Regeneration
19%
Chagas Cardiomyopathy
19%
D-dimer
19%
Left Atrial Thrombus
19%
Diagnostic Accuracy
19%
Combination Immunotherapy
19%
Natriuretic Peptides
19%
Early Gastric Cancer
19%
Endoscopic Submucosal Dissection
19%
Ringer
19%
Pericarditis
19%
In-hospital Management
19%
Normal Saline
19%
Subnational Analysis
19%
Leadless Pacemaker
19%
Nationwide Database
19%
Cardiac Ablation
19%
Delayed Initiation
19%
Gastric Neoplasms
19%
Time Management
19%
Real-world Outcomes
19%
Trial Enrollment
19%
Propensity-matched Analysis
19%
Severe Acute Pancreatitis
19%
Hypertonic Saline Solution
19%
Monotherapy
19%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
90%
Disease
76%
Coronavirinae
76%
Heart Infarction
43%
Coronary Artery Disease
43%
All Cause Mortality
39%
Acute Heart Infarction
38%
Lopinavir Plus Ritonavir
38%
Colchicine
38%
Hydroxychloroquine
38%
Random Effects Model
32%
Cardiovascular Mortality
29%
Prevalence
28%
Cardiovascular Disease
24%
Carbohydrate Antigen
19%
Integrase Inhibitor
19%
Acute Cholecystitis
19%
Capillary Hemangioma
19%
Chagas Cardiomyopathy
19%
Gingiva Disease
19%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
19%
Influenza Vaccine
19%
Restrictive Cardiomyopathy
19%
Constrictive Pericarditis
19%
Natriuretic Factor
19%
Acute Coronary Syndrome
19%
Bacterial Endocarditis
19%
Ringer Lactate Solution
19%
Azithromycin
19%
Malignant Neoplasm
19%
Probiotic Agent
19%
Infection
19%
Physical Disability
19%
Immunotherapy
19%
Prasugrel
19%
Obesity
19%
Terminal Illness
19%
Adverse Event
19%
Azithromycin Plus Chloroquine
19%
Frailty
19%
Jejunum Ulcer
19%
Peptic Ulcer Bleeding
19%
Cardiovascular Risk
19%
HIV
19%
Peripartum Cardiomyopathy
19%
Cohort Study
15%
Bromocriptine
12%
Clopidogrel
12%
Retrospective Study
11%
Cross-Sectional Study
11%
Medicine and Dentistry
Meta-Analysis
76%
Systematic Review
57%
Primary Percutaneous Coronary Intervention
22%
Percutaneous Aortic Valve Replacement
19%
Carbohydrate Antigen
19%
Acute Cholecystitis
19%
Restrictive Cardiomyopathy
19%
Constrictive Pericarditis
19%
Gallbladder Drainage
19%
Percutaneous Transhepatic Drainage
19%
Endoscopic Submucosal Dissection
19%
Capillary Hemangioma
19%
Enamel Matrix Derivative
19%
Diagnostic Performance
19%
Heart Atrium Thrombosis
19%
Diagnostic Accuracy
19%
Pacemaker Implantation
19%
Pericarditis
19%
D-Dimer
19%
Neoplasm
19%
Atrial Fibrillation
19%
Hospital Management
19%
Heart Right Ventricle Function
19%
Acute Heart Infarction
19%
Catheter Ablation
19%
Physical Disability
19%
Acute Coronary Syndrome
19%
Immunotherapy
19%
Probiotic Agent
19%
Integrase Inhibitor
19%
Clinical Research
19%
COVID-19
19%
Pulmonary Artery Catheterization
19%
Endoscopic Hemostasis
19%
Implantable Automatic Defibrillator
19%
Hypertrophic Obstructive Cardiomyopathy
19%
Alcohol Septal Ablation
19%
Non ST Segment Elevation Myocardial Infarction
19%
Cardiovascular Risk
19%
Human Immunodeficiency Virus
19%
ST Segment Elevation Myocardial Infarction
19%
Peripartum Cardiomyopathy
19%
CHA2DS2-VASc Score
19%
Takotsubo Cardiomyopathy
19%
Frailty
19%
Apoplexy
17%
Hazard Ratio
16%
Coronary Angiography
14%
Percutaneous Coronary Intervention
13%
Muscle Resection
12%